Alcon (ALC) CMD 2025 summary

Strategic priorities and market outlook

• Focus on resilient, growing eye care markets driven by aging populations, rising myopia, and increasing global wealth, with a $35B addressable market expected to grow at mid-single digits over the next five years.

• Shift to a second strategic horizon emphasizing operational excellence, digital transformation, and accelerated R&D productivity to drive efficiency and innovation.

• Commitment to outpacing market growth through targeted investments, aiming for 6%-8% annual revenue growth and 12%-15% core EPS growth over a five-year horizon.

• R&D reinvestment of 8%-10% of revenue, with over $5B invested since 2018 and more than 100 active programs supporting multiple near-term product launches.

• Capital allocation priorities: organic investment, disciplined M&A (typically $50M-$500M deals), and shareholder returns via dividends and buybacks, with a 10% payout policy.

Financial performance and guidance

• Net sales grew from $7.4B in 2019 to $9.8B in 2024, with core operating margin rising from 17.2% to 20.6%.

• Free cash flow increased from $367M in 2019 to $1.6B in 2024, with a shift to a 90% cash conversion metric for future guidance, placing the company in the top quartile of its sector.

• 2025 guidance: net sales of $10.8–$11.0B, core operating margin of 24–25%, and free cash flow of ~$1.8–$2.0B.

• Margin expansion is expected to continue, primarily through operating leverage and efficiency gains from shared services and digital process improvements.

• Long-term guidance excludes M&A except for the Aurion Biotech acquisition, which will cause near-term earnings pressure but is expected to contribute revenue from 2028-2029.

Innovation and product pipeline

• Seven new products are launching in the first half of the year, including Unity VCS, PanOptix Pro, Voyager, Unity DX, Systane Pro, Precision7, and AR-15512.

• UNITY VCS/CS platform and next-gen consumables are launching in 2025, driving efficiency in cataract and vitreoretinal surgery and annuity revenue streams.

• PanOptix Pro and Vivity upgrades aim to further increase ATIOL penetration, with each point of penetration representing a $100M revenue opportunity.

• Precision7, the first one-week lens, and TOTAL30 multifocal toric are set to expand share in specialty and reusable contact lenses.

• AR-15512 (Acoltremon) targets rapid, sustained relief for dry eye, with a PDUFA date in May and a dedicated sales force ready for launch.